Gastroparesis is a disorder characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach, resulting in the cardinal symptoms of early satiety, postprandial fullness, nausea, vomiting, belching, and bloating. Gastroparesis is now recognized as part of a broader spectrum of gastric neuromuscular dysfunction that includes impaired gastric accommodation.
The most common cause of Gastroparesis is diabetes mellitus type 1 or type 2. High levels of glucose in the blood can cause chemical changes to the vagus nerve. Gastroparesis is typically associated with some form of damage to the vagus nerve, which can occur in a range of situations, including from various mineral deficiencies, eating disorders, opioid medications, certain antidepressants, and surgeries in the upper gastrointestinal tract, such as gastrectomy or bariatric surgery.
Get FREE sample copy at:
The Gastroparesis market report also covers emerging drugs, current treatment practices, Gastroparesis market share of the individual therapies, current and forecasted Gastroparesis Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Gastroparesis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Gastroparesis Market Key Facts
The total prevalent population of Gastroparesis in the 7MM ranges from 33,690,400 in 2017 during the study period [2017–2030] and is expected to increase by 2030.
The United States witnessed the highest number of cases with Gastroparesis, as compared to other 7MM countries. In addition to this, the estimates show the highest prevalence of Gastroparesis in the United States with 13,019,321 cases in 2017.
Among the European-5 countries, Germany had the highest prevalent population of Gastroparesis with 5,443,684 cases, followed by Spain and Italy. On the other hand, the United Kingdom had the lowest prevalent population of Gastroparesis, i.e., 1,966,549 in 2017. Furthermore, Japan had 5,785,669 prevalent cases for Gastroparesis in 2017.
Among the major types of Gastroparesis, i.e., Idiopathic, Diabetic, and Post-surgical Gastroparesis, the former one account for a higher number of Gastroparesis cases.
Key Benefits of Gastroparesis Market Report
Gastroparesis market report provides an in-depth analysis of Gastroparesis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
The Gastroparesis market report will help in developing business strategies by understanding the Gastroparesis Market trends & developments, key players, and future market competition that will shape and drive the Gastroparesis market in the upcoming years.
The Gastroparesis market report covers Gastroparesi’s current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Gastroparesis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Gastroparesis market size is expected to increase owing to the launch of upcoming therapies during the forecast period.
The Gastroparesis market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Gastroparesis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Gastroparesis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
A higher percentage of prevalence of Gastroparesis was observed for females, in comparison to males, in all the 7MM countries.
The Gastroparesis epidemiology section covers insights about the historical and current Gastroparesis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Gastroparesis Drugs Uptake and Key Market Players
The Gastroparesis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroparesis market or expected to get launched in the market during the study period. The analysis covers Gastroparesis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Gastroparesis market is anticipated to change in the coming years owing to the improvement in the diagnostic methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period.
Major Pharma giants are thoroughly working toward the development of new treatment therapies for Gastroparesis, to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with Gastroparesis.
Bird Rock Bio
And may others.
Gastroparesis therapies covered in the report include:
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Gastroparesis Competitive Intelligence Analysis
4. Gastroparesis Market Overview at a Glance
5. Gastroparesis Disease Background and Overview
6. Gastroparesis Patient Journey
7. Gastroparesis Epidemiology and Patient Population
8. Gastroparesis Treatment Algorithm, Current Treatment, and Medical Practices
9. Gastroparesis Unmet Needs
10. Key Endpoints of Gastroparesis Treatment
11. Gastroparesis Marketed Products
12. Gastroparesis Emerging Therapies
13. Gastroparesis Seven Major Market Analysis
14. Attribute Analysis
15. Gastroparesis Market Outlook (7 major markets)
16. Gastroparesis Access and Reimbursement Overview
17. KOL Views on the Gastroparesis Market.
18. Gastroparesis Market Drivers
19. Gastroparesis Market Barriers
21. DelveInsight Capabilities
Gastroparesis Epidemiology Forecast
DelveInsight’s Gastroparesis – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Gastroparesis in 7MM.
Gastroparesis Pipeline Insights
Gastroparesis Pipeline Insight, 2020 report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Gastroparesis market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd. 2432
City: Las Vegas
Country: United States